Evidence map›Paper›PMID 39420046›Full record

SynthesisScientific reports2024

A systematic review and meta-analysis of GFAP gene variants in Alexander disease.

Alice Grossi, Francesca Rosamilia, Silvia Carestiato, Ettore Salsano, Isabella Ceccherini, Tiziana Bachetti

Abstract readMeta-AnalysisSystematic Review
In one paragraph

Synthesis in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Diagnosing Alexander disease in adults.Practical neurology · 2025
    Review
  5. Self-silencingJournal of neurology, neurosurgery, and psychiatry · 2025
    Article
  6. "Frog face and strangulated medulla": neuroimaging phenotype in a novel mutation in GFAP gene causing adult onset Alexander disease.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  7. PepTune:ArXiv · 2025
    Article
  8. Genotype-Phenotype Association for 14Neurology. Genetics · 2025
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alice Grossi *Laboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, 16147, Italy.
Francesca Rosamilia *Clinical Bioinformatics, IRCCS Istituto Giannina Gaslini, Genoa, 16147, Italy.
Silvia CarestiatoDepartment of Neurosciences, Rita Levi Montalcini University of Turin, Turin, 10126, Italy.
Ettore SalsanoSC Malattie Neurologiche Rare, Fondazione IRCCS Istituto Neurologico C. Besta, Milano, Italy.
Isabella CeccheriniLaboratory of Genetics and Genomics of Rare Diseases, IRCCS Istituto Giannina Gaslini, Genoa, 16147, Italy. isabellaceccherini@gaslini.org.
Tiziana BachettiIRCCS Ospedale Policlinico San Martino, Genova, Italy.

Funding

Association "Più Unici Che Rari" fellowshipItalian Ministry of Health "Ricerca Corrente" and "5 x mille" to ICItalian Ministry of Health "Ricerca Corrente" n. N774A to T.B.
6 · The paper itself

Abstract

Alexander disease (ALXDRD) is a rare neurodegenerative disorder of astrocytes resulting from pathogenic variants in the GFAP gene. The genotype-phenotype correlation remains elusive due to the variable expressivity of clinical manifestations. In an attempt to clarify the effects of GFAP variants in ALXDRD, numerous studies were collected and analyzed. In particular, we systematically searched for GFAP variants associated with ALXDRD and collected information on the location within the gene and protein, prediction of deleteriousness/pathogenicity, occurrence, sex and country of origin of patients, DNA source, genetic testing, and clinical signs. To identify possible associations, statistical analyses and meta-analyses were applied, thus revealing a higher than expected percentage of adult patients with ALXDRD. Furthermore, substitution of Arginine, the most frequently altered residue among the 550 predominantly missense causative GFAP variants collected, were mostly de novo and more prevalent in early-onset forms of ALXDRD. The effect of defective splicing in modifying the impact of GFAP variants on the age of onset of ALXDRD was also postulated after evaluating the distribution of the corresponding deleterious predictive values. In conclusion, not only previously unrecognized genotype-phenotype correlations were revealed in ALXDRD, but also subtle mechanisms could explain the variable manifestations of the ALXDRD clinical phenotype.

Indexed as

Alexander DiseaseGlial Fibrillary Acidic ProteinFemaleGenetic Association StudiesHumansMalePhenotypeGFAP protein, humanGlial Fibrillary Acidic ProteinAlexander DiseaseGenotype-phenotype correlationGFAPMeta-analysisVariant effect

Identifiers

PMID39420046
PMCPMC11487261

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.